Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease

Chronic granulomatous disease (CGD) is an inherited blood disorder of phagocytic cells that renders patients susceptible to infections and inflammation. A recent clinical trial of lentiviral gene therapy for the most frequent form of CGD, X-linked, has demonstrated stable correction over time, with no adverse events related to the gene therapy procedure. We have recently developed a parallel lentiviral vector for p47^phox-deficient CGD (p47^phoxCGD), the second most common form of this disease. Using this vector, we have observed biochemical correction of CGD in a mouse model of the disease. In preparation for clinical trial approval, we have performed standardized preclinical studies following Good Laboratory Practice (GLP) principles, to assess the safety of the gene therapy procedure. We report no evidence of adverse events, including mutagenesis and tumorigenesis, in human hematopoietic stem cells transduced with the lentiviral vector. Biodistribution studies of transduced human CD34⁺ cells indicate that the homing properties or engraftment ability of the stem cells is not negatively affected. CD34⁺ cells derived from a p47^phoxCGD patient were subjected to an optimized transduction protocol and transplanted into immunocompromised mice. After the procedure, patient-derived neutrophils resumed their function, suggesting that gene correction was successful. These studies pave the way to a first-in-man clinical trial of lentiviral gene therapy for the treatment of p47^phoxCGD.

Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome

IMPORTANCE

Wiskott-Aldrich syndrome is a rare primary immunodeficiency associated with severe microthrombocytopenia. Partially HLA antigen-matched allogeneic hematopoietic stem cell (HSC) transplantation is often curative but is associated with significant comorbidity.

OBJECTIVE

To assess the outcomes and safety of autologous HSC gene therapy in Wiskott-Aldrich syndrome.

DESIGN, SETTING, AND PARTICIPANTS

Gene-corrected autologous HSCs were infused in 7 consecutive patients with severe Wiskott-Aldrich syndrome lacking HLA antigen-matched related or unrelated HSC donors (age range, 0.8-15.5 years; mean, 7 years) following myeloablative conditioning. Patients were enrolled in France and England and treated between December 2010 and January 2014. Follow-up of patients in this intermediate analysis ranged from 9 to 42 months.

INTERVENTION

A single infusion of gene-modified CD34+ cells with an advanced lentiviral vector.

MAIN OUTCOMES AND MEASURES

Primary outcomes were improvement at 24 months in eczema, frequency and severity of infections, bleeding tendency, and autoimmunity and reduction in disease-related days of hospitalization. Secondary outcomes were improvement in immunological and hematological characteristics and evidence of safety through vector integration analysis.

RESULTS

Six of the 7 patients were alive at the time of last follow-up (mean and median follow-up, 28 months and 27 months, respectively) and showed sustained clinical benefit. One patient died 7 months after treatment of preexisting drug-resistant herpes virus infection. Eczema and susceptibility to infections resolved in all 6 patients. Autoimmunity improved in 5 of 5 patients. No severe bleeding episodes were recorded after treatment, and at last follow-up, all 6 surviving patients were free of blood product support and thrombopoietic agonists. Hospitalization days were reduced from a median of 25 days during the 2 years before treatment to a median of 0 days during the 2 years after treatment. All 6 surviving patients exhibited high-level, stable engraftment of functionally corrected lymphoid cells. The degree of myeloid cell engraftment and of platelet reconstitution correlated with the dose of gene-corrected cells administered. No evidence of vector-related toxicity was observed clinically or by molecular analysis.

CONCLUSIONS AND RELEVANCE

This study demonstrated the feasibility of the use of gene therapy in patients with Wiskott-Aldrich syndrome. Controlled trials with larger numbers of patients are necessary to assess long-term outcomes and safety.

Expression of TREM-1 in Macrophages is TLR2 dependent (51.7)

Triggering receptors expressed on myeloid cells (TREM) are a group of cell surface proteins that contribute to inflammation, allergy, bone homeostasis, neurological development and coagulation, among other cellular processes. Specifically, activation of TREM-1 on monocytes has been shown to enhance the synthesis of multiple proinflammatory cytokines, chemokines and cell surface molecules in the presence of Toll-like receptor (TLR) specific pathogen associated molecular patterns (PAMPs). Presently, little is known about the regulatory role of TLRs on TREM-1 expression and function in macrophages. Accordingly, we examined the expression and function of TREM-1 in bone marrow derived macrophages (BMMØ) from non-sensitized and Aspergillus fumigatus sensitized wild type C57BL/6 (WT) and TLR2 deficient mice (TLR2−/−). In naïve WT BMMØ, TREM-1 expression was upregulated by IFNγ. BMMØ from naïve TLR2−/− mice did not express TREM-1 transcripts nor was it altered by cytokine or PAMP activation. In the context of sensitization, WT BMMØ expressed greater TREM-1 levels when compared with naive WT BMMØ. TREM-1 was detected in sensitized TLR2 −/− BMMØ but at much lower levels than sensitized WT BMMØ. Finally, both IFNγ and IL-13 increased expression of TREM-1 sensitized WT and TLR2−/− BMMØ. Thus, TLR2 expression was required for TREM-1 expression by BMMØ. Also, TREM-1 expression is markedly increased in BMMØ derived from allergic mice confirming a role for this receptor in allergic responses. Thus, regulation of TREM-1 expression may be a therapeutic target in allergic airway disease.

HL069865